Date: Wednesday, October 14th, 2020 at 7:00 PM EDT / 4:00 PM PDT
- To understand cost implications for biosimilars
- To understand the potential issues and benefits of switching
- To provide the nursing perspective on the use of biosimilars
- To provide the patient perspective on the use of biosimilars
- To provide the pharmacist perspective on the use of biosimilars and highlight the impact on pharmacovigilance
- To discuss the ethical implications surrounding the implementation/use of a oncology biosimilars in clinical practice
Dr. Scott Berry
Dr. Christine Brezden-Masley
Dr. Stephen Chia
Dr. John Hilton
Dr. Scott Edwards
Dr. Sandeep Sehdev
This webinar has been made possible through sponsorship from Mylan
Registration is complimentary for healthcare professionals. Click the button below to register:
Dr. Scott Berry is a medical oncologist and Professor and Department Head in the Queen's University Department of Oncology. He is the Cancer Program Medical Director at the Cancer Centre of Southeastern Ontario at the Kingston Health Sciences Centre. Dr. Berry is an active participant in clinical research in GI cancer. He is the Co-Chair of the GI Disease Site Group of the CCO Program in Evidence Based Care. Dr. Berry has won several teaching awards and is a past Chair of the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology. His other academic interest is the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry has a Master’s degree in Bioethics from the University of Toronto. He is the former ethics advisor to the pan-Canadian Oncology Drug Review and has served on the ASCO Ethics Committee.
Dr. Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunefeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada. Dr Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.
Dr. Stephen Chia, MD, FRCP, is a Professor of Medicine in the Department of Medicine at the University of British Columbia, Vancouver, Canada. He is the co-chair of the CCTG Breast Disease Site and a member of the NCI Breast Cancer Steering Committee. He also is a staff medical oncologist with the British Columbia Cancer Agency (BCCA), Vancouver Centre. Dr. Chia also serves as Chair for the British Columbia Breast Tumour Group, Chair of the BCCA Tumour Group Council, and is the Associate Director for Clinical Research at the BC Cancer Agency. He is a Subject Editor for the British Journal of Cancer and The Oncologist. As well he is section author in UpToDate for the Prognostic/Predictive Markers in Metastatic Breast Cancer Section. He has over 155 peer reviewed publications and numerous grants from various funding agencies.
Dr. John Hilton is a Clinician Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and an Associate Professor of Medicine at the University of Ottawa. He also serves as the Research Lead for Breast Cancer Disease site as well as the organizational Lead for the Clinical Trials Office within the Ottawa Hospital Cancer Centre. His primary clinical expertise and research focus is to improve clinical care for patients with breast cancer and head and neck cancer as well as early drug development for patients with advanced, metastatic disease.
Dr. Scott Edwards
Bio coming soon!
Swanee Tobin is a Nurse Practitioner in Medical Oncology with a specialty in Breast and Gastrointestinal malignancies working in Toronto at Mount Sinai Hospital. She graduated from the University of Toronto with a Masters of Nursing in 2008 and a Nurse Practitioner Adult Certificate in 2012.
Dr. Sandeep Sehdev practices Medical Oncology at the Ottawa Hospital Cancer Centre and the affiliated Ivan Greenberg Family Cancer Centre at the Queensway Carleton Hospital. He is also a Clinical Investigator at the Ottawa Hospital Cancer Centre. Dr. Sehdev obtained his MD at the University of Ottawa. He began his Internal Medicine training at the Western University before his oncology training in Toronto, where he served as a Chief Resident in 1991. He worked at the William Osler Health System serving Brampton, Etobicoke, Orangeville and environs from 1991-2016 where he was director of continuing health education (oncology) and the clinical trials program. He also served as CHE lead for the Community Oncologists of Metropolitan Toronto. His major disease sites include breast, genitourinary cancers and melanoma. His interests lie in medical education, patient and community education, applications of technology in oncology and advocacy He was a past Director of the Cancer Advocacy Coalition of Canada and a current Director of PACCT (Physician Alliance for Cancer Control and Treatment).
For more information, please send requests to Robyn Leonard at firstname.lastname@example.org.